Early cancer imaging study halted after limited testing
NCT ID NCT04712721
Summary
This was an early, first-in-human study to test a new radioactive imaging agent called [68Ga]-FF58. The goal was to see if it could safely and effectively highlight specific aggressive cancers (like glioblastoma and pancreatic cancer) during PET scans. The study was terminated early, so only 14 patients were enrolled to evaluate the tracer's initial safety and imaging performance.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.